- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | GENELUX Corp - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| Do | GENELUX Corp - 8-K, Current Report | 1 | SEC Filings | ||
| Do | Genelux GAAP EPS of -$0.86 misses by $0.01 | 1 | Seeking Alpha | ||
| Do | Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | 566 | GlobeNewswire (Europe) | -- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses... ► Artikel lesen | |
| Do | GENELUX Corp - 10-K, Annual Report | 2 | SEC Filings | ||
| 02.02. | GENELUX Corp - 8-K, Current Report | 4 | SEC Filings | ||
| GENELUX Aktie jetzt für 0€ handeln | |||||
| 12.01. | Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners | 4 | GlobeNewswire (USA) | ||
| 09.01. | Weekly Buzz: ScinoPharm Gets FDA Nod; Genelux's Olvi-Vec Shows Promise; Monte Rosa Therapeutics' MRT-8102 Advances | 490 | AFX News | PARIS (dpa-AFX) - The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis.... ► Artikel lesen | |
| 08.01. | Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock | 5 | GlobeNewswire (USA) | ||
| 07.01. | Genelux kündigt öffentliches Angebot von Stammaktien an | 3 | Investing.com Deutsch | ||
| 07.01. | Genelux announces proposed public offering | 1 | Seeking Alpha | ||
| 07.01. | Genelux Corporation Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 05.01. | Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data | 3 | Investing.com | ||
| 05.01. | Genelux-Aktie: Positive Studiendaten stützen Kaufempfehlung von H.C. Wainwright | 3 | Investing.com Deutsch | ||
| 02.01. | GENELUX Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 02.01. | Genelux Corp Appoints Jason Litten CMO | 3 | RTTNews | ||
| 02.01. | Genelux appoints Jason Litten as chief medical officer | 1 | Investing.com | ||
| 02.01. | Genelux beruft Jason Litten zum neuen Chief Medical Officer | 3 | Investing.com Deutsch | ||
| 02.01. | Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer | 187 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D.... ► Artikel lesen | |
| 05.11.25 | Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates | 167 | GlobeNewswire (Europe) | -- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 --... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INFLARX | 0,811 | -0,67 % | InflaRx N.V.: InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones | Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aRSubstantial progress made toward Phase 2b readiness... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,320 | 0,00 % | RedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells | Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as... ► Artikel lesen | |
| IMMUNIC | 0,930 | -4,71 % | Immunic auf dem Stifel CNS Forum: Strategische Einblicke in MS-Medikament | ||
| CURIS | 0,690 | +5,34 % | Curis, Inc.: Curis Provides Fourth Quarter 2025 Business Update | Management to host conference call today at 4:30 p.m. ET
LEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused... ► Artikel lesen | |
| ESPERION | 2,205 | +0,23 % | Esperion Therapeutics, Inc.: Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia | - Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,372 | +4,10 % | BioXcel Therapeutics stock initiated with buy rating at Rodman | ||
| CYBIN | 4,040 | -1,46 % | Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer | Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industryAppointment supports Helus Pharma's continued maturation as the company... ► Artikel lesen | |
| KYNTRA BIO | 6,050 | +0,83 % | Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and... ► Artikel lesen | |
| KARYOPHARM | 7,250 | +9,85 % | Karyopharm Therapeutics Inc.: Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress | - Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 -
- Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer... ► Artikel lesen | |
| BIOLINERX | 2,095 | -3,90 % | BioLineRx FY 2025 Earnings Preview | ||
| PROTALIX BIOTHERAPEUTICS | 1,890 | +2,16 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EDT
The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio®... ► Artikel lesen | |
| EDESA BIOTECH | 6,500 | +5,69 % | Edesa Biotech, Inc.: Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study | Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files provisional... ► Artikel lesen | |
| CAN-FITE BIOPHARMA | 3,215 | -2,87 % | Can-Fite receives Israeli patent for obesity treatment use | ||
| BRIACELL THERAPEUTICS | 3,920 | +8,89 % | BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting | PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 4,200 | -1,41 % | Sagimet Biosciences Inc.: Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates | Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026... ► Artikel lesen |
GENELUX CORPORATION gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,380 Euro und damit -6,30 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENELUX CORPORATION finden Sie auf Wallstreet Online.